Search

Your search keyword '"Fourquet, Alain"' showing total 829 results
Start Over Author "Fourquet, Alain"
829 results on '"Fourquet, Alain"'

1. The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies

Author

Kaidar-Person, Orit, Boersma, Liesbeth J., De Brouwer, Peter, Weltens, Caroline, Kirkove, Carine, Peignaux-Casasnovas, Karine, Budach, Volker, van der Leij, Femke, Peters, Max, Weidner, Nicola, Rivera, Sofia, van Tienhoven, Geertjan, Fourquet, Alain, Noel, Georges, Valli, Mariacarla, Guckenberger, Matthias, Koiter, Eveline, Racadot, Severine, Abdah-Bortnyak, Roxolyana, Bartelink, Harry, Struikmans, Henk, Fortpied, Catherine, and Poortmans, Philip M.

Published
2024
Full Text
View/download PDF

3. Mapping the location of local and regional recurrences according to breast cancer surgery and radiation therapy: Results from EORTC 22922/10925

Author

Kaidar-Person, Orit, Giasafaki, Peggy, Boersma, Liesbeth, De Brouwer, Peter, Weltens, Caroline, Kirkove, Carine, Peignaux-Casasnovas, Karine, Budach, Volker, van der Leij, Femke, Vonk, Ernest, Weidner, Nicola, Rivera, Sofia, van Tienhoven, Geertjan, Fourquet, Alain, Noel, Georges, Valli, Mariacarla, Guckenberger, Matthias, Koiter, Eveline, Racadot, Severine, Abdah-Bortnyak, Roxolyana, Bartelink, Harry, Struikmans, Henk, Fortpied, Catherine, and Poortmans, Philip M.

Published
2023
Full Text
View/download PDF

9. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

Author

Poortmans, Philip M, Weltens, Caroline, Fortpied, Catherine, Kirkove, Carine, Peignaux-Casasnovas, Karine, Budach, Volker, van der Leij, Femke, Vonk, Ernest, Weidner, Nicola, Rivera, Sofia, van Tienhoven, Geertjan, Fourquet, Alain, Noel, Georges, Valli, Mariacarla, Guckenberger, Matthias, Koiter, Eveline, Racadot, Severine, Abdah-Bortnyak, Roxolyana, Van Limbergen, Erik F, Engelen, Antoine, De Brouwer, Peter, Struikmans, Henk, and Bartelink, Harry

Published
2020
Full Text
View/download PDF

13. Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia–Telangiectasia Mutated Variant Carriers.

Author

Bensenane, Rayan, Beddok, Arnaud, Lesueur, Fabienne, Fourquet, Alain, Warcoin, Mathilde, Le Mentec, Marine, Cavaciuti, Eve, Le Gal, Dorothée, Eon-Marchais, Séverine, Andrieu, Nadine, Stoppa-Lyonnet, Dominique, and Kirova, Youlia

Subjects
RISK assessment, STATISTICAL models, LYMPHEDEMA, THERAPEUTIC complications, RADIOTHERAPY, RESEARCH funding, SKIN inflammation, BREAST tumors, GENETIC markers, SCIENTIFIC observation, FISHER exact test, ATAXIA telangiectasia, CANCER patients, RETROSPECTIVE studies, RADIATION dosimetry, DESCRIPTIVE statistics, CHI-squared test, FIBROSIS, KAPLAN-Meier estimator, ESTROGEN receptors, FLUORESCENCE in situ hybridization, GENETIC mutation, RADIATION doses, DATA analysis software, ALLELES, GENOTYPES, SINGLE nucleotide polymorphisms, SEQUENCE analysis, EPIDERMAL growth factor receptors, DEGLUTITION disorders
Abstract

Simple Summary: Of the worldwide population, 0.5 to 1% of people are carrying a heterozygous mutation of Ataxia–Telangiectasia Mutated (ATM) gene. While the clinical radiosensitivity of carriers of germline biallelic inactivation of the ATM gene is well described, controversies are observed for monoallelic carriers of ATM mutation. The aim of this study is to evaluate acute and late toxicities after adjuvant breast radiation therapy in ATM pathogenic variant carriers. This observational retrospective study showed an absence of significative acute and late toxicities after breast radiation therapy among patients carrying a heterozygous rare variant of the ATM gene. Single nucleotide polymorphism rs1801516 (G/A), described as associated with late subcutaneous fibrosis, was not associated with this late adverse event in our study. The Ataxia–Telangiectasia Mutated (ATM) gene is implicated in DNA double-strand break repair. Controversies in clinical radiosensitivity remain known for monoallelic carriers of the ATM pathogenic variant (PV). An evaluation of the single-nucleotide polymorphism (SNP) rs1801516 (G-A) showed different results regarding late subcutaneous fibrosis after breast radiation therapy (RT). The main objective of this study was to evaluate acute and late toxicities in carriers of a rare ATM PV or predicted PV and in carriers of minor allele A of rs1801516 facing breast RT. Fifty women with localized breast cancer treated with adjuvant RT between 2000 and 2014 at Institut Curie were selected. Acute and late toxicities in carriers of a rare PV or predicted PV (n= 9), in noncarriers (n = 41) and in carriers of SNP rs1801516 (G-A) (n = 8), were examined. The median age at diagnosis was 53 years old and 82% of patients had an invasive ductal carcinoma and 84% were at clinical stage I–IIB. With a median follow-up of 13 years, no significant difference between carriers and noncarriers was found for acute toxicities (p > 0.05). The same results were observed for late toxicities without an effect from the rs1801516 genotype on toxicities. No significant difference in acute or late toxicities was observed between rare ATM variant carriers and noncarriers after breast RT for localized breast cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes

Author

Kaidar-Person, Orit, Fortpied, Catherine, Hol, Sandra, Weltens, Caroline, Kirkove, Carine, Budach, Volker, Peignaux-Casasnovas, Karine, van der Leij, Femke, Vonk, Ernest, Valli, Mariacarla, Weidner, Nicola, Guckenberger, Matthias, Koiter, Eveline, Fourquet, Alain, Bartelink, Harry, Struikmans, Henk, Poortmans, Philip, EORTC Radiation Oncology and Breast Cancer Groups, EORTC Radiation Oncology and Breast Cancer Groups, Radiotherapie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, UCL - (SLuc) Service de radiothérapie oncologique, University of Zurich, and Kaidar-Person, Orit

Subjects
QUALITY-ASSURANCE, 2720 Hematology, 610 Medicine & health, Breast Neoplasms, HEART-DISEASE, BREAST-CANCER RADIOTHERAPY, THERAPY, Disease-Free Survival, Breast cancer, MASTECTOMY, 2741 Radiology, Nuclear Medicine and Imaging, Humans, Radiology, Nuclear Medicine and imaging, Breast, Thoracic Wall, RECURRENCE, Lymph nodes, Computer. Automation, RISK, Radiotherapy, MORTALITY, WOMEN, Hematology, 10044 Clinic for Radiation Oncology, Quality assurance, Techniques, EORTC, Oncology, 2730 Oncology, Female, CHAIN IRRADIATION, Lymph Nodes, Human medicine
Abstract

BACKGROUND AND PURPOSE: The multicentre EORTC 22922/10925 trial (ClinicalTrials.gov, NCT00002851) was conducted between 1996 and 2004. The trial evaluated the effect of irradiation of the internal mammary and medial supraclavicular lymph node chains (IM-MS) vs no further radiation therapy (RT) on survival and cause of death in breast cancer stage I-III patients. At 15.7 years of median follow-up, a significant reduction of breast cancer specific mortality (BCSM) and any recurrence, not translating in improved overall survival (OS), and low absolute rates of side effects were found. The aim of the current analysis was to evaluate the association of RT techniques of IM-MS lymph node irradiation with long-term outcomes.PATIENTS AND METHODS: Three RT techniques were used for IM-MS: a standard technique using a fixed set-up combining photon/electron beams to the IM and tangential fields to the breast or chest wall vs a standard-modified technique with minor adaptation for beam settings vs a more individualised technique based on individual localisation of the IM. Techniques used were fixed per institution over the duration of the trial. We performed an exploratory and descriptive analysis of the outcomes after 15 years follow-up for the three RT techniques.RESULTS: Between July 1996 and January 2004, 46 radiation oncology departments from 13 countries accrued 4004 patients. Median follow-up was 15.7 years. The number of patients treated by each technique was 2440 (61%) by standard vs 635 (16%) by standard-modified vs 929 (23%) patients by individualised technique. The absolute improvements of oncological outcomes in terms of disease-free survival (DFS), OS and BCSM with IM-MS RT compared to no IM-MS RT were 6.8%, 4.9% and -5.8% for the individualised technique, vs 1.6%, 2.9% and -4.3% for modified standard and -1.4%, 1.1% and -3% for standard technique, respectively. The increase in 15-year rates of side effects due to IM-MS RT, both scored longitudinally and cross-sectionally, were similar among the techniques.CONCLUSION: Even though a straightforward comparison by technique is not possible because of variations in baseline characteristics between institutions, our findings suggest that the use of more individualised RT techniques is associated with higher rates of oncological improvements without increased risks for late side effects.

Published
2022

25. Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.

Author

Beddok, Arnaud, Mouren, Victoire, Cottu, Paul, Laki, Fatima, Fourquet, Alain, and Kirova, Youlia

Subjects
HORMONE receptor positive breast cancer, METASTATIC breast cancer, CYCLIN-dependent kinase inhibitors, ERIBULIN, PROGNOSIS, LOG-rank test, PULMONARY fibrosis
Abstract

The objective of the present study was to assess the outcomes and toxicity of patients treated with concurrent administration of CDK4/6 inhibitors (CDK4/6i) and locoregional radiation therapy (RT), including the breast with a boost or the thoracic wall after mastectomy and the regional lymph node areas. We retrospectively analyzed data from 27 patients with hormone receptor‐positive, HER2‐negative de novo metastatic breast cancer treated with CDK4/6i and concomitant locoregional RT in 2017/2022. Survival rates were calculated by Kaplan‐Meier method. Prognostic factors were tested with log‐rank test. CDK4/6i was used as the first systemic metastatic treatment for all the patients, and the median overall treatment time was 26 months. The median time from initiation of CDK4/6i to the start of RT was 10 months (IQR: 7‐14 months). The median duration of concomitant CDK4/6i and RT administration was 21 days (IQR: 14.5‐23 days). After a median follow‐up of 19 months (IQR: 14‐36 months), 1 patient died, 11/27 had distant metastases and 1 patient had local recurrence, respectively. The 1‐ and 3‐years progression‐free survival (PFS) were 61.4% (95% CI: 45.1%‐83.7%) and 53.7% (35.8%‐80.5%), respectively. The acute toxicities most observed during RT were neutropenia (44%) and dermatitis (37%). Dermatitis was significantly more frequent in patients with large target volumes (CTV > 911 cc and PTV > 1285 cc). CDK4/6i had to be discontinued in five patients during RT (due to toxicity in three cases and disease progression in two cases). One patient has developed grade 2 late pulmonary fibrosis. Finally, our study demonstrated that concurrent administration of locoregional RT and CDK4/6i did not induce severe late toxicity for most patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Supplementary Table S1 from Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast

Author

Vincent-Salomon, Anne, primary, Lucchesi, Carlo, primary, Gruel, Nadège, primary, Raynal, Virginie, primary, Pierron, Gaëlle, primary, Goudefroye, Rémi, primary, Reyal, Fabien, primary, Radvanyi, François, primary, Salmon, Rémy, primary, Thiery, Jean-Paul, primary, Sastre-Garau, Xavier, primary, Sigal-Zafrani, Brigitte, primary, Fourquet, Alain, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

27. Data from Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women

Author

Servant, Nicolas, primary, Bollet, Marc A., primary, Halfwerk, Hans, primary, Bleakley, Kevin, primary, Kreike, Bas, primary, Jacob, Laurent, primary, Sie, Daoud, primary, Kerkhoven, Ron M., primary, Hupé, Philippe, primary, Hadhri, Rim, primary, Fourquet, Alain, primary, Bartelink, Harry, primary, Barillot, Emmanuel, primary, Sigal-Zafrani, Brigitte, primary, and van de Vijver, Marc J., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast

Author

Vincent-Salomon, Anne, primary, Lucchesi, Carlo, primary, Gruel, Nadège, primary, Raynal, Virginie, primary, Pierron, Gaëlle, primary, Goudefroye, Rémi, primary, Reyal, Fabien, primary, Radvanyi, François, primary, Salmon, Rémy, primary, Thiery, Jean-Paul, primary, Sastre-Garau, Xavier, primary, Sigal-Zafrani, Brigitte, primary, Fourquet, Alain, primary, and Delattre, Olivier, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Tables 1-4, Figure 1 from Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women

Author

Servant, Nicolas, primary, Bollet, Marc A., primary, Halfwerk, Hans, primary, Bleakley, Kevin, primary, Kreike, Bas, primary, Jacob, Laurent, primary, Sie, Daoud, primary, Kerkhoven, Ron M., primary, Hupé, Philippe, primary, Hadhri, Rim, primary, Fourquet, Alain, primary, Bartelink, Harry, primary, Barillot, Emmanuel, primary, Sigal-Zafrani, Brigitte, primary, and van de Vijver, Marc J., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 1 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas

Author

Reyal, Fabien, primary, Stransky, Nicolas, primary, Bernard-Pierrot, Isabelle, primary, Vincent-Salomon, Anne, primary, de Rycke, Yann, primary, Elvin, Paul, primary, Cassidy, Andrew, primary, Graham, Alexander, primary, Spraggon, Carolyn, primary, Désille, Yoann, primary, Fourquet, Alain, primary, Nos, Claude, primary, Pouillart, Pierre, primary, Magdelénat, Henri, primary, Stoppa-Lyonnet, Dominique, primary, Couturier, Jérôme, primary, Sigal-Zafrani, Brigitte, primary, Asselain, Bernard, primary, Sastre-Garau, Xavier, primary, Delattre, Olivier, primary, Thiery, Jean Paul, primary, and Radvanyi, François, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 2 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas

Author

Reyal, Fabien, primary, Stransky, Nicolas, primary, Bernard-Pierrot, Isabelle, primary, Vincent-Salomon, Anne, primary, de Rycke, Yann, primary, Elvin, Paul, primary, Cassidy, Andrew, primary, Graham, Alexander, primary, Spraggon, Carolyn, primary, Désille, Yoann, primary, Fourquet, Alain, primary, Nos, Claude, primary, Pouillart, Pierre, primary, Magdelénat, Henri, primary, Stoppa-Lyonnet, Dominique, primary, Couturier, Jérôme, primary, Sigal-Zafrani, Brigitte, primary, Asselain, Bernard, primary, Sastre-Garau, Xavier, primary, Delattre, Olivier, primary, Thiery, Jean Paul, primary, and Radvanyi, François, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 4 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas

Author

Reyal, Fabien, primary, Stransky, Nicolas, primary, Bernard-Pierrot, Isabelle, primary, Vincent-Salomon, Anne, primary, de Rycke, Yann, primary, Elvin, Paul, primary, Cassidy, Andrew, primary, Graham, Alexander, primary, Spraggon, Carolyn, primary, Désille, Yoann, primary, Fourquet, Alain, primary, Nos, Claude, primary, Pouillart, Pierre, primary, Magdelénat, Henri, primary, Stoppa-Lyonnet, Dominique, primary, Couturier, Jérôme, primary, Sigal-Zafrani, Brigitte, primary, Asselain, Bernard, primary, Sastre-Garau, Xavier, primary, Delattre, Olivier, primary, Thiery, Jean Paul, primary, and Radvanyi, François, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 3 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas

Author

Reyal, Fabien, primary, Stransky, Nicolas, primary, Bernard-Pierrot, Isabelle, primary, Vincent-Salomon, Anne, primary, de Rycke, Yann, primary, Elvin, Paul, primary, Cassidy, Andrew, primary, Graham, Alexander, primary, Spraggon, Carolyn, primary, Désille, Yoann, primary, Fourquet, Alain, primary, Nos, Claude, primary, Pouillart, Pierre, primary, Magdelénat, Henri, primary, Stoppa-Lyonnet, Dominique, primary, Couturier, Jérôme, primary, Sigal-Zafrani, Brigitte, primary, Asselain, Bernard, primary, Sastre-Garau, Xavier, primary, Delattre, Olivier, primary, Thiery, Jean Paul, primary, and Radvanyi, François, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 2 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas

Author

Reyal, Fabien, primary, Stransky, Nicolas, primary, Bernard-Pierrot, Isabelle, primary, Vincent-Salomon, Anne, primary, de Rycke, Yann, primary, Elvin, Paul, primary, Cassidy, Andrew, primary, Graham, Alexander, primary, Spraggon, Carolyn, primary, Désille, Yoann, primary, Fourquet, Alain, primary, Nos, Claude, primary, Pouillart, Pierre, primary, Magdelénat, Henri, primary, Stoppa-Lyonnet, Dominique, primary, Couturier, Jérôme, primary, Sigal-Zafrani, Brigitte, primary, Asselain, Bernard, primary, Sastre-Garau, Xavier, primary, Delattre, Olivier, primary, Thiery, Jean Paul, primary, and Radvanyi, François, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 1 from Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas

Author

Reyal, Fabien, primary, Stransky, Nicolas, primary, Bernard-Pierrot, Isabelle, primary, Vincent-Salomon, Anne, primary, de Rycke, Yann, primary, Elvin, Paul, primary, Cassidy, Andrew, primary, Graham, Alexander, primary, Spraggon, Carolyn, primary, Désille, Yoann, primary, Fourquet, Alain, primary, Nos, Claude, primary, Pouillart, Pierre, primary, Magdelénat, Henri, primary, Stoppa-Lyonnet, Dominique, primary, Couturier, Jérôme, primary, Sigal-Zafrani, Brigitte, primary, Asselain, Bernard, primary, Sastre-Garau, Xavier, primary, Delattre, Olivier, primary, Thiery, Jean Paul, primary, and Radvanyi, François, primary

Published
2023
Full Text
View/download PDF

41. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial

Author

Bartelink, Harry, Maingon, Philippe, Poortmans, Philip, Weltens, Caroline, Fourquet, Alain, Jager, Jos, Schinagl, Dominic, Oei, Bing, Rodenhuis, Carla, Horiot, Jean-Claude, Struikmans, Henk, Van Limbergen, Erik, Kirova, Youlia, Elkhuizen, Paula, Bongartz, Rudolf, Miralbell, Raymond, Morgan, David, Dubois, Jean-Bernard, Remouchamps, Vincent, Mirimanoff, René-Olivier, Collette, Sandra, and Collette, Laurence

Published
2015
Full Text
View/download PDF

43. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer

Author

Loap, Pierre, primary, Loirat, Delphine, additional, Berger, Frederique, additional, Rodrigues, Manuel, additional, Bazire, Louis, additional, Pierga, Jean-Yves, additional, Vincent-Salomon, Anne, additional, Laki, Fatima, additional, Boudali, Latifa, additional, Raizonville, Laurence, additional, Mosseri, Veronique, additional, Jochem, Anne, additional, Eeckhoutte, Alexandre, additional, Diallo, Mamadou, additional, Stern, Marc-Henri, additional, Fourquet, Alain, additional, and Kirova, Youlia, additional

Published
2022
Full Text
View/download PDF

47. The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trial.

Author

UCL - (SLuc) Service de radiothérapie oncologique, Kaidar-Person, Orit, Fortpied, Catherine, Hol, Sandra, Weltens, Caroline, Kirkove, Carine, Budach, Volker, Peignaux-Casasnovas, Karine, van der Leij, Femke, Vonk, Ernest, Valli, Mariacarla, Weidner, Nicola, Guckenberger, Matthias, Koiter, Eveline, Fourquet, Alain, Bartelink, Harry, Struikmans, Henk, Poortmans, Philip, EORTC Radiation Oncology and Breast Cancer Groups, UCL - (SLuc) Service de radiothérapie oncologique, Kaidar-Person, Orit, Fortpied, Catherine, Hol, Sandra, Weltens, Caroline, Kirkove, Carine, Budach, Volker, Peignaux-Casasnovas, Karine, van der Leij, Femke, Vonk, Ernest, Valli, Mariacarla, Weidner, Nicola, Guckenberger, Matthias, Koiter, Eveline, Fourquet, Alain, Bartelink, Harry, Struikmans, Henk, Poortmans, Philip, and EORTC Radiation Oncology and Breast Cancer Groups

Abstract

The multicentre EORTC 22922/10925 trial (ClinicalTrials.gov, NCT00002851) was conducted between 1996 and 2004. The trial evaluated the effect of irradiation of the internal mammary and medial supraclavicular lymph node chains (IM-MS) vs no further radiation therapy (RT) on survival and cause of death in breast cancer stage I-III patients. At 15.7 years of median follow-up, a significant reduction of breast cancer specific mortality (BCSM) and any recurrence, not translating in improved overall survival (OS), and low absolute rates of side effects were found. The aim of the current analysis was to evaluate the association of RT techniques of IM-MS lymph node irradiation with long-term outcomes. Three RT techniques were used for IM-MS: a standard technique using a fixed set-up combining photon/electron beams to the IM and tangential fields to the breast or chest wall vs a standard-modified technique with minor adaptation for beam settings vs a more individualised technique based on individual localisation of the IM. Techniques used were fixed per institution over the duration of the trial. We performed an exploratory and descriptive analysis of the outcomes after 15 years follow-up for the three RT techniques. Between July 1996 and January 2004, 46 radiation oncology departments from 13 countries accrued 4004 patients. Median follow-up was 15.7 years. The number of patients treated by each technique was 2440 (61%) by standard vs 635 (16%) by standard-modified vs 929 (23%) patients by individualised technique. The absolute improvements of oncological outcomes in terms of disease-free survival (DFS), OS and BCSM with IM-MS RT compared to no IM-MS RT were 6.8%, 4.9% and -5.8% for the individualised technique, vs 1.6%, 2.9% and -4.3% for modified standard and -1.4%, 1.1% and -3% for standard technique, respectively. The increase in 15-year rates of side effects due to IM-MS RT, both scored longitudinally and cross-sectionally, were similar among the techniques. Even thoug

Published
2022

49. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial

Author

Vrieling, Conny, van Werkhoven, Erik, Maingon, Philippe, Poortmans, Philip, Weltens, Caroline, Fourquet, Alain, Schinagl, Dominic, Oei, Bing, Rodenhuis, Carla C., Horiot, Jean-Claude, Struikmans, Henk, Van Limbergen, Erik, Kirova, Youlia, Elkhuizen, Paula, Bongartz, Rudolf, Miralbell, Raymond, Morgan, David A. L., Dubois, Jean-Bernard, Remouchamps, Vincent, Mirimanoff, René-Olivier, Hart, Guus, Collette, Sandra, Collette, Laurence, and Bartelink, Harry

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results